

Table S1. The clinicopathological characteristics of 253 patients with breast cancer for IHC analysis were presented.

Parameters		Number of cases	Percentage (%)
Gender	Female	253	100.0
Age (years)	≤50	114	45.1
	>50	139	54.9
Pathological type	IDC	224	88.5
	Other	29	11.5
T classification	T ₁	110	43.5
	T ₂	108	42.7
	T ₃	32	12.6
	T ₄	3	1.2
N classification	N ₀	132	52.2
	N ₁	95	37.5
	N ₂	21	8.3
	N ₃	5	2.0
M classification	M ₀	246	97.2
	M ₁	7	2.8
Clinical stage	I	105	41.5
	II	91	36.0
	III	50	19.8
	IV	7	2.8
Pathological grade	G ₁	84	33.2
	G ₂	90	35.6
	G ₃	79	31.2
Survival status	Live	150	59.3
	Dead	103	40.7
Distant metastasis status (Exclude M ₁)	Negative	130	52.8
	Positive	116	47.2

IHC status of TMSB10	Low	99	39.1
	High	154	60.9
IHC status of ER	Negative	121	47.8
	Positive	132	52.2
IHC status of PR	Negative	89	35.2
	Positive	164	64.8
IHC status of HER2	Negative	182	71.9
	Positive	71	28.1
IHC status of Ki67	Low	150	59.3
	High	103	40.7

Abbreviation: Invasive ductal carcinoma (IDC), Immunological Histological Chemistry (IHC), Estrogen receptor (ER), Progesterone receptor (PR).